Read by QxMD icon Read

Delman melanoma

Lauren M Postlewait, Clara R Farley, Maggie L Diller, Benjamin Martin, M Hart Squires, Maria C Russell, Monica Rizzo, Kenneth Ogan, Viraj Master, Keith Delman
BACKGROUND: Open inguinal lymphadenectomy (OIL) has a high incidence of complications. The authors adapted and reported a minimally invasive technique [videoscopic inguinal lymphadenectomy (VIL)] for use with melanoma, subsequently pursuing a randomized, prospective trial comparing open and minimally invasive approaches in an attempt to confirm retrospective findings illustrating reduced complications with the minimally invasive approach. METHODS: A randomized, prospective trial (NCT01526486) was designed to compare outcomes for patients undergoing VIL versus OIL...
August 2, 2017: Annals of Surgical Oncology
Maggie L Diller, Ragini R Kudchadkar, Keith A Delman, David H Lawson, Mandy L Ford
Th17 cells represent a distinct subset of CD4 effector T cells with potent pathogenic qualities, capable of directly mediating tumor cell destruction. IL-2 has frequently been shown to have a negative effect on Th17 differentiation while supporting regulatory T-cell (FoxP3CD4, TREG) growth and development in both in vitro models and in vivo animal models. We investigated the effect of in vivo IL-2 on both the Th17 and FoxP3CD4 T-cell compartments in a human model of cancer. High-dose IL-2 (HDIL-2) was administered at a dose of 720,000 IU/kg to patients with melanoma (n=7) and peripheral blood was collected at baseline and at 24, 48, 72, and 96 hours posttreatment...
November 2016: Journal of Immunotherapy
H Danish, K Patel, J Switchenko, T W Gillespie, J Jhaveri, M Chowdhary, M Abugideiri, K A Delman, D H Lawson, M K Khan
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Hasan H Danish, Kirtesh R Patel, Jeffrey M Switchenko, Theresa W Gillespie, Jaymin Jhaveri, Mudit Chowdhary, Mustafa Abugideiri, Keith A Delman, David H Lawson, Mohammad K Khan
Recently, TROG 02.01 results showed that in stage III melanoma patients with nodal metastasis, adjuvant radiation to lymph node basin after nodal dissection improves lymph node field relapse without an overall survival (OS) benefit. However, this trial was neither designed nor powered to detect an OS difference. In the present study, we analyzed patients in the National Cancer Database (NCDB) with stage III melanoma with pathologically involved nodes and compared survival outcomes of adjuvant radiation and no-radiation cohorts...
December 2016: Melanoma Research
Brendan P Lovasik, Ishna Sharma, Maria C Russell, Grant W Carlson, Keith A Delman, Monica Rizzo
BACKGROUND: Scalp and neck melanomas (SNMs) have a relatively poor prognosis compared to other sites, and represent an anatomically challenging area for detection. The aim of this study was to identify the role of the hairdresser in detection of SNMs. METHODS: A tertiary surgical oncology institutional database was retrospectively reviewed for all patients undergoing resection of a scalp, posterior neck, or retro auricular invasive primary melanoma between 2008 and 2014...
November 2016: Annals of Surgical Oncology
Maggie L Diller, Ragini R Kudchadkar, Keith A Delman, David H Lawson, Mandy L Ford
High-dose IL-2 (HDIL-2) is associated with complete and durable responses in only 5-10% of patients with stage intravenous melanoma and the toxicity profile is significant. In-vivo human models have recently shown a stimulatory effect of exogenous IL-2 on both the Th17 and regulatory T-cell (TREG) compartments. We investigated and compared the effect of HDIL-2 on the Th17 and TREG compartments in HDIL-2 responders versus nonresponders. HDIL-2 was administered at a dose of 720 000 IU/kg to patients with melanoma (n=6) and peripheral blood was collected at baseline and at 24, 48, 72, and 96 h during treatment...
October 2016: Melanoma Research
Robert H I Andtbacka, Merrick Ross, Igor Puzanov, Mohammed Milhem, Frances Collichio, Keith A Delman, Thomas Amatruda, Jonathan S Zager, Lee Cranmer, Eddy Hsueh, Lisa Chen, Mark Shilkrut, Howard L Kaufman
PURPOSE: Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In this study, we describe the patterns and time course of response to T-VEC from the phase III OPTiM trial of 436 patients with unresected stages IIIB-IV melanoma. METHODS: Lesion-level response analyses were performed based on the type of lesion (injected or uninjected cutaneous, subcutaneous, or nodal lesions; or visceral lesions [uninjected]), and the best percentage change from baseline of the sum of products of the longest diameters was calculated...
December 2016: Annals of Surgical Oncology
Kevin E Fisher, Linsheng Zhang, Jason Wang, Geoffrey H Smith, Scott Newman, Thomas M Schneider, Rathi N Pillai, Ragini R Kudchadkar, Taofeek K Owonikoko, Suresh S Ramalingam, David H Lawson, Keith A Delman, Bassel F El-Rayes, Malania M Wilson, H Clifford Sullivan, Annie S Morrison, Serdar Balci, N Volkan Adsay, Anthony A Gal, Gabriel L Sica, Debra F Saxe, Karen P Mann, Charles E Hill, Fadlo R Khuri, Michael R Rossi
We tested and clinically validated a targeted next-generation sequencing (NGS) mutation panel using 80 formalin-fixed, paraffin-embedded (FFPE) tumor samples. Forty non-small cell lung carcinoma (NSCLC), 30 melanoma, and 30 gastrointestinal (12 colonic, 10 gastric, and 8 pancreatic adenocarcinoma) FFPE samples were selected from laboratory archives. After appropriate specimen and nucleic acid quality control, 80 NGS libraries were prepared using the Illumina TruSight tumor (TST) kit and sequenced on the Illumina MiSeq...
March 2016: Journal of Molecular Diagnostics: JMD
Cecilia G Ethun, Keith A Delman
Optimization of margins to minimize morbidity and maximize local control is critical to the success of surgical management of primary melanomas. This article synthesizes the historical perspectives and key clinical trials that have contributed to the evolution of resection margins for melanoma, focusing on the importance of surgical margins in the context of an era of improvements in systemic therapy and greater use of minimally invasive techniques.
March 2016: Journal of Surgical Oncology
Clara Farley, Yewande Alimi, Lauren R Espinosa, Sebastian Perez, William Knechtle, Andrea Hestley, Grant W Carlson, Maria C Russell, Keith A Delman, Monica Rizzo
BACKGORUND AND OBJECTIVES: Melanoma is steadily increasing over the past decade. Recent studies confirmed a link between tanning bed use and melanoma. We sought to determine the prevalence and frequency of tanning bed among young patients with melanoma. METHODS: We retrospectively analyzed tanning bed use among young melanoma patients compared to controls selected from the hospital medical records. A telephone survey investigated family history of melanoma or skin cancer, hair color, eye color, skin type, tanning bed use, and patient awareness of dangers of tanning bed use...
August 2015: Journal of Surgical Oncology
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A Delman, Lynn E Spitler, Igor Puzanov, Sanjiv S Agarwala, Mohammed Milhem, Lee Cranmer, Brendan Curti, Karl Lewis, Merrick Ross, Troy Guthrie, Gerald P Linette, Gregory A Daniels, Kevin Harrington, Mark R Middleton, Wilson H Miller, Jonathan S Zager, Yining Ye, Bin Yao, Ai Li, Susan Doleman, Ari VanderWalde, Jennifer Gansert, Robert S Coffin
PURPOSE: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III trial. PATIENTS AND METHODS: Patients with injectable melanoma that was not surgically resectable were randomly assigned at a two-to-one ratio to intralesional T-VEC or subcutaneous GM-CSF...
September 1, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Maggie L Diller, Benjamin M Martin, Keith A Delman
Locoregional spread of melanoma to its draining lymph node basin is the strongest negative prognostic factor for patients. Exclusive of clinical trials, patients with sentinel lymph node-positive (microscopic) or clinically palpable (macroscopic) nodal disease should undergo lymphadenectomy. This article reviews the management and technical aspects of surgical care for regional metastases. Adjunct therapies (immunotherapy, targeted therapy, and radiation) may supplement lymphadenectomy in certain patient populations...
April 2015: Surgical Oncology Clinics of North America
Pedram Gerami, Robert W Cook, Maria C Russell, Jeff Wilkinson, Rodabe N Amaria, Rene Gonzalez, Stephen Lyle, Gilchrist L Jackson, Anthony J Greisinger, Clare E Johnson, Kristen M Oelschlager, John F Stone, Derek J Maetzold, Laura K Ferris, Jeffrey D Wayne, Chelsea Cooper, Roxana Obregon, Keith A Delman, David Lawson
BACKGROUND: A gene expression profile (GEP) test able to accurately identify risk of metastasis for patients with cutaneous melanoma has been clinically validated. OBJECTIVE: We aimed for assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients. METHODS: Reverse transcription polymerase chain reaction (RT-PCR) was performed to assess the expression of 31 genes from primary melanoma tumors, and SLNB outcome was determined from clinical data...
May 2015: Journal of the American Academy of Dermatology
Maria C Russel, Keith A Delman
The worldwide incidence of melanoma continues to rise. It is a leading cause of cancer death and the second leading cause of loss of productive years of life. Although the diagnosis of melanoma is straightforward, there remain many controversies regarding treatment and surveillance. This chapter addresses important questions in melanoma treatment such as sentinel lymph node biopsy, what to do with a positive sentinel lymph node, margins of resection for melanoma, radiation for primary, nodal and metastatic melanoma, and routine use imaging...
2015: Cancer Treatment and Research
David Delman, Xianming Peng, Daniel C Zedek, Valerie Jewells, Nizar Chahin, Silva Markovic-Plese
IMPORTANCE: This is the first report of neuromyelitis optica spectrum disorder (NMOSD) associated with dermatomyositis (DM). REPORT: A 40year-old Caucasian female presented with 6months of worsening fatigue, rash, acute weakness worse in her lower extremities, and urinary retention. She was found to have both NMOSD and anti-melanoma differentiation-associated gene (MDA)5 positive DM with interstitial lung disease (ILD). She was treated aggressively and she regained her ability to ambulate...
January 15, 2015: Journal of Neuroimmunology
Daniel E Oliver, Kirtesh R Patel, Douglas Parker, Keith A Delman, David H Lawson, Ragini R Kudchadkar, Mohammad K Khan
The National Comprehensive Cancer Network (NCCN) 2014 guidelines are unclear about the role of radiotherapy in the management of desmoplastic melanoma. The guidelines specify that radiotherapy can be 'considered' for select patients with desmoplastic melanoma with narrow surgical margins. Patient selection criteria, including margins, are not well defined, causing considerable differences in practice patterns across the country. There are also several conflicting reports about the role of radiotherapy in improving postsurgical outcomes when other adverse pathological risks factors, such as increased Clark level, head and neck involvement, perineural invasion, positive margins, or recurrent disease, are also present...
April 2015: Melanoma Research
Pedram Gerami, Robert W Cook, Jeff Wilkinson, Maria C Russell, Navneet Dhillon, Rodabe N Amaria, Rene Gonzalez, Stephen Lyle, Clare E Johnson, Kristen M Oelschlager, Gilchrist L Jackson, Anthony J Greisinger, Derek Maetzold, Keith A Delman, David H Lawson, John F Stone
PURPOSE: The development of a genetic signature for the identification of high-risk cutaneous melanoma tumors would provide a valuable prognostic tool with value for stage I and II patients who represent a remarkably heterogeneous group with a 3% to 55% chance of disease progression and death 5 years from diagnosis. EXPERIMENTAL DESIGN: A prognostic 28-gene signature was identified by analysis of microarray expression data. Primary cutaneous melanoma tumor tissue was evaluated by RT-PCR for expression of the signature, and radial basis machine (RBM) modeling was performed to predict risk of metastasis...
January 1, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Benjamin M Martin, Joanna W Etra, Maria C Russell, Monica Rizzo, David A Kooby, Charles A Staley, Viraj A Master, Keith A Delman
BACKGROUND: Open inguinal lymphadenectomy for regionally metastatic melanoma is associated with a high wound-related morbidity. Videoscopic inguinal lymphadenectomy (VIL) is a minimally invasive approach with fewer wound-related complications, yet its adoption has been hindered by a lack of oncologic outcomes data. STUDY DESIGN: Data were prospectively collected on all VILs performed for melanoma from 2008 to 2012 (n = 40) and compared with a retrospective cohort of open superficial inguinal lymphadenectomies from 2005 to 2012 (n = 40)...
April 2014: Journal of the American College of Surgeons
Benjamin M Martin, Viraj A Master, Keith A Delman
The selection of a treatment modality involves a balance between risk and benefit. Surgical decision making is intrinsically dependent on potential morbidity; therefore, the desire to minimize adverse outcomes remains paramount in the effort to provide patients with the widest range of therapeutic options. The adoption of sentinel lymph node biopsy for the evaluation of regionally metastatic melanoma has reduced the number of complete lymphadenectomies and their attendant comorbidities. For patients who require completion lymphadenectomy, selective lymphadenectomy and, more recently, videoscopic inguinal lymphadenectomy have been shown to further reduce wound-related complications, while maintaining equivalent regional control and lymph node yield, respectively...
October 2013: Oncology (Williston Park, NY)
Benjamin M Martin, Viraj A Master, Keith A Delman
BACKGROUND: The standard treatment of care for melanoma metastatic to the inguinal lymph node basin is lymphadenectomy. However, up to 50% of patients forgo the operation partly due to concerns about morbidity. Videoscopic inguinal lymphadenectomy (VIL) is a minimally invasive technique designed to minimize wound complications while achieving comparable oncological control. METHODS: We reviewed pertinent literature related to open inguinal lymphadenectomy and VIL specific to melanoma, offering personal experience where appropriate...
October 2013: Cancer Control: Journal of the Moffitt Cancer Center
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"